What is the purpose of this trial?
The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL). PROCLAIM: PRObody CLinical Assessment In Man CX-2029 clinical trial 001
PROBODY is a trademark of CytomX Therapeutics, Inc
CytomX Therapeutics, Inc.
Start Date: 02/20/2019
End Date: 05/01/2020
Last Updated: 02/21/2019
Study HIC#: 2000023250